Andrew P. Greening

The frequency of, and adherence to, single maintenance and reliever therapy instructions in asthma: a descriptive analysis

Rachael L. DiSantostefano, Nada Boudiaf, David A. Stempel, Neil C. Barnes et autres

Inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) fixed-dose combinations are recommended regular maintenance options for asthma. ICS/LABAs containing formoterol may also be indicated for single maintenance and reliever therapy (SMART). This analysis evaluated the frequency of SMART dosing of budesonide/formoterol fixed-dose combination (BFC) in the …

us (code pays fourni par la source)

Patient information sheets

Eric W.F.W. Alton, David K Armstrong, Deborah Ashby, Katie J Bayfield et autres

Safety and adverse events

Eric W.F.W. Alton, David K Armstrong, Deborah Ashby, Katie J Bayfield et autres

A randomised, double-blind, placebo-controlled trial of repeated nebulisation of non-viral cystic fibrosis transmembrane conductance regulator (CFTR) gene therapy in patients with cystic fibrosis

Eric W.F.W. Alton, David K Armstrong, Deborah Ashby, Katie J Bayfield et autres

Background Cystic fibrosis (CF) is a chronic, life-limiting disease caused by mutations in the CF transmembrane conductance regulator (CFTR) gene leading to abnormal airway surface ion transport, chronic lung infections, inflammation and eventual respiratory failure. With the exception of the small-molecule potentiator, …

gb, us, fr (code pays fourni par la source)

Cystic Fibrosis Questionnaire – Revised quality-of-life questionnaire

Eric W.F.W. Alton, David K Armstrong, Deborah Ashby, Katie J Bayfield et autres

Methods: clinical trial design and outcome measures

Eric W.F.W. Alton, David K Armstrong, Deborah Ashby, Katie J Bayfield et autres

Dose preparation sheet

Eric W.F.W. Alton, David K Armstrong, Deborah Ashby, Katie J Bayfield et autres

Results of mechanistic substudy

Eric W.F.W. Alton, David K Armstrong, Deborah Ashby, Katie J Bayfield et autres

Results of clinical efficacy outcomes

Eric W.F.W. Alton, David K Armstrong, Deborah Ashby, Katie J Bayfield et autres

Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial

Eric W.F.W. Alton, David K Armstrong, Deborah Ashby, Katie J Bayfield et autres

BACKGROUND: Lung delivery of plasmid DNA encoding the CFTR gene complexed with a cationic liposome is a potential treatment option for patients with cystic fibrosis. We aimed to assess the efficacy of non-viral CFTR gene therapy in patients with cystic fibrosis. METHODS: …

gb, us, fr (code pays fourni par la source)

Measurement of Serum Calprotectin in Stable Patients Predicts Exacerbation and Lung Function Decline in Cystic Fibrosis

Philip A. Reid, David McAllister, Alan C. Boyd, J. Alastair Innes et autres

To the Editor: Clinical tests that predict clinical outcomes in cystic fibrosis (CF) such as exacerbation risk and lung function decline are lacking. Calprotectin (MRP8/14, S100A8/A9) is an abundant neutrophil protein found in bronchoalveolar lavage fluid (1), sputum (2), and serum of …

gb (code pays fourni par la source)

Assessment of immune responses to single and repeat dose aeroslisation of the non-viral formualtion PGM169/GL67A in cystic fibrosis patients

Uta Griesenbach, Eric W.F.W. Alton, David K Armstrong, Katie J Bayfield et autres